Search results for "Colore"

showing 10 items of 1250 documents

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague–Dawley Rats But Aflibercept Affects…

2019

Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents. These biologics, however, possess a distinct toxicity profile, and they may also exacerbate the adverse effects of traditional chemotherapeutics. In this study, we aimed to characterize the gastrointestinal and metabolic changes after a 2-week treatment period with aflibercept, an antiangiogenic VEGFR decoy, and with erlotinib, a tyrosine-kinase inhibitor. Male rats were treated either with aflibercept or erlotinib for 2 weeks. During the 2-week treatment period, the animals in …

0301 basic medicineOriginal articleCancer ResearchBevacizumabANTITUMOR-ACTIVITYmedicine.medical_treatmentBEVACIZUMAB3122 CancersAdipose tissuePharmacologylcsh:RC254-282TOXICITY03 medical and health sciences0302 clinical medicinemedicineOXIDATIVE STRESSCOMBINATIONAdverse effectAfliberceptChemotherapyIntestinal permeabilitybusiness.industryCHEMOTHERAPYmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMETASTATIC COLORECTAL-CANCER1ST-LINE TREATMENT030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSACIDToxicityErlotinibbusinessmedicine.drug
researchProduct

Bericht zum 1. Workshop zur lokalen Exzision von Rektumkarzinomen

2007

To determine the significance of local excision (LE) of rectal cancer and discuss oncologic results, a 1st Workshop on LE of rectal cancer was held at the Department of General und Abdominal Surgery, Johannes Gutenberg-University Mainz, Germany. The option of broadening the indication for local excision after neoadjuvant radiochemotherapy (nRCT) of rectal cancer was to be assessed. Local excision of "low risk" T 1 carcinomas was rated as oncologically adequate therapy with good functional results and low complication rates. Transanal endoscopic microsurgical (TEM) resection was the preferrred technique. Pre-requisite for the achievement of low recurrence rates (5 %) is an R0 resection with …

medicine.medical_specialtymedicine.diagnostic_testColorectal cancerbusiness.industrymedicine.medical_treatmentMicrosurgerymedicine.diseaseProctoscopySurgerymedicine.anatomical_structureTumor buddingmedicineCarcinomaResection marginSurgerybusinessLymph nodeAbdominal surgeryZentralblatt für Chirurgie
researchProduct

PO-182 The upregulation of EPDR1 is related to tumour invasiveness in a cohort of localised colorectal cancer patients

2018

Introduction Colorectal cancer (CRC) represents a relevant public health problem. Despite new therapeutic advances, prognosis of patients diagnosed with advanced disease is still poor. The identification of new markers involved in the mechanisms of invasiveness represents a priority in order to better understand cancer development and generate new therapeutic targets. We describe here the possible role of EPDR1, a gene not yet well characterised, which encodes a protein related to ependymins, a family of piscine transmembrane proteins involved in cell adhesion. To evaluate the role of EPDR1, a translational investigation was planned to explore the consequences of the upregulation of EPDR1 i…

OncologyCancer Researchmedicine.medical_specialtyGene knockdownNecrosisCell growthColorectal cancerbusiness.industrymedicine.diseaseOncologyDownregulation and upregulationInternal medicineCohortmedicineGene silencingmedicine.symptombusinessGrading (tumors)ESMO Open
researchProduct

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

2013

Background Tumor models are critical for our understanding of cancer and the development of cancer therapeutics. Here, we present an integrated map of the genome, transcriptome and immunome of an epithelial mouse tumor, the CT26 colon carcinoma cell line. Results We found that Kras is homozygously mutated at p.G12D, Apc and Tp53 are not mutated, and Cdkn2a is homozygously deleted. Proliferation and stem-cell markers, including Top2a, Birc5 (Survivin), Cldn6 and Mki67, are highly expressed while differentiation and top-crypt markers Muc2, Ms4a8a (MS4A8B) and Epcam are not. Myc, Trp53 (tp53), Mdm2, Hif1a, and Nras are highly expressed while Egfr and Flt1 are not. MHC class I but not MHC class…

Neuroblastoma RAS viral oncogene homologmedicine.disease_causeMajor histocompatibility complexPolymorphism Single NucleotideProto-Oncogene Proteins p21(ras)TranscriptomeMiceAntigenAntigens NeoplasmCDKN2ACell Line TumorMHC class ImedicineGeneticsAnimalsCancer modelsComputational immunologyCyclin-Dependent Kinase Inhibitor p16Mice Inbred BALB CMHC class IIbiologyCarcinomaHigh-Throughput Nucleotide SequencingSequence Analysis DNAColorectal cancerMolecular biologyColonic Neoplasmsbiology.proteinImmunotherapyKRASTranscriptomeResearch ArticleBiotechnologyBMC Genomics
researchProduct

Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma.

2006

It is well established that cancer arises in chronically inflamed tissue, and this is particularly notable in the gastrointestinal tract. Classic examples include Helicobacter pylori-associated gastric cancer, hepatocellular carcinoma, and inflammatory bowel disease-associated colorectal cancer. Growing evidence suggests that these associations might be not casual findings. Focusing on individual cytokines has generated evidence that anti-inflammatory cytokine interleukin (IL)-10 and transforming growth factor-beta1 (TGF-beta1) may have a complex role in gastrointestinal carcinogenesis. As an example, IL-10-deficient mice develop severe atrophic gastritis and a chronic enterocolitis, develo…

gene polymorphismsMaleRiskProlineColorectal cancerAtrophic gastritisil-10colorectal cancerMouse model of colorectal and intestinal cancerBiologymedicine.disease_causePolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyMetastasisTransforming Growth Factor beta1colorectal cancercytokine genepolymorphismsHistory and Philosophy of ScienceGene FrequencyLeucineGenotypemedicineHumansGenetic Predisposition to DiseaseAllelesGeneral Neurosciencetgf-β1CarcinomaCancermedicine.diseaseInterleukin-10Amino Acid SubstitutionItalyTumor progressionCase-Control StudiesImmunologycolorectal cancer; gene polymorphisms; il-10; tgf-β1FemaleCarcinogenesisColorectal NeoplasmsAnnals of the New York Academy of Sciences
researchProduct

Predictors of complications and mortality following left colectomy with primary stapled anastomosis for cancer: results of a multicentric study with …

2018

Aim Reports detailing the morbidity-mortality after left colectomy are sparse and do not allow definitive conclusions to be drawn. We aimed to identify risk factors for anastomotic leakage, perioperative mortality and complications following left colectomy for colonic malignancies. Method We undertook a STROBE-compliant analysis of left colectomies included in a national prospective online database. Forty-two variables were analysed as potential independent risk factors for anastomotic leakage, postoperative morbidity and mortality. Variables were selected using the 'least absolute shrinkage and selection operator' (LASSO) method. Results We analysed 1111 patients. Eight per cent of patient…

Malemedicine.medical_specialtyColectomiesDatabases FactualColorectal cancerColonanastomotic leak030230 surgeryLower risk03 medical and health sciencesLiver disease0302 clinical medicineRisk FactorsSurgical StaplingmedicineHumansstapled anastomosipostoperative complicationProspective Studiesleft colectomyColectomyAgedbusiness.industryAnastomosis SurgicalGastroenterologyPostoperative complicationPerioperativeMiddle Agedmedicine.diseaseSurgeryColon cancerParenteral nutritionTreatment Outcome030220 oncology & carcinogenesisColonic NeoplasmsFemalebusinessComplication
researchProduct

Individualized Comprehensive Lifestyle Intervention in Patients Undergoing Chemotherapy with Curative or Palliative Intent: Who Participates?

2015

Objective Knowledge about determinants of participation in lifestyle interventions in cancer patients undergoing chemotherapy, particularly with palliative intent, remains poor. The objective of the present study was to identify determinants of participating in a 12 month individualized, comprehensive lifestyle intervention, focusing on diet, physical activity, mental stress and smoking cessation, in cancer patients receiving chemotherapy with curative or palliative intent. The secondary objective was to identify participation determinants 4 months into the study. Methods Newly diagnosed cancer patients starting chemotherapy at the cancer center in Kristiansand/Norway (during a 16 month inc…

Malemedicine.medical_specialtyPalliative caremedicine.medical_treatmentlcsh:MedicineAntineoplastic AgentsBreast NeoplasmsBreast cancerInternal medicinemedicineHumansPrecision Medicinelcsh:ScienceLife StyleSocioeconomic statusAgedChemotherapyMultidisciplinarybusiness.industryPalliative Carelcsh:RProstatic NeoplasmsCancerMiddle Agedmedicine.diseaseCombined Modality TherapyPhysical therapySmoking cessationMarital statusFemaleSmoking Cessationlcsh:QColorectal NeoplasmsbusinessBody mass indexResearch ArticlePLOS ONE
researchProduct

Colorectal Cancer Stem Cells: From the Crypt to the Clinic

2014

Since their first discovery, investigations of colorectal cancer stem cells (CSCs) have revealed some unexpected properties, including a high degree of heterogeneity and plasticity. By exploiting a combination of genetic, epigenetic, and microenvironmental factors, colorectal CSCs metastasize, resist chemotherapy, and continually adapt to a changing microenvironment, representing a formidable challenge to cancer eradication. Here, we review the current understanding of colorectal CSCs, including their origin, relationship to stem cells of the intestine, phenotypic characterization, and underlying regulatory mechanisms. We also discuss limitations to current preclinical models of colorectal …

Pluripotent Stem CellsColorectal cancerAnimals; Colonic Neoplasms; Colorectal Neoplasms; Disease Models Animal; Gene Expression Regulation Neoplastic; Humans; Intestines; Neoplastic Stem Cells; Pluripotent Stem Cells; Tumor EscapeCryptAnimals; Colonic Neoplasms; Colorectal Neoplasms; Disease Models Animal; Gene Expression Regulation Neoplastic; Humans; Intestines; Neoplastic Stem Cells; Pluripotent Stem Cells; Tumor Escape; Molecular Medicine; Genetics; Cell BiologyBiologySettore MED/04 - PATOLOGIA GENERALEmedicineGeneticsAnimalsHumansEpigeneticsRegulation of gene expressionNeoplasticAnimalCancerCell Biologymedicine.diseasePhenotypeGene Expression Regulation NeoplasticIntestinesDisease Models AnimalTumor EscapeGene Expression RegulationImmunologyColonic NeoplasmsDisease ModelsCancer researchNeoplastic Stem CellsMolecular MedicineTumor EscapeStem cellColorectal Neoplasmscolorectal cancer stem cells CSCsCell Stem Cell
researchProduct

Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases : a population-based study

2020

Background This population‐based study aimed to examine the incidence, patterns and results of multimodal management of metastatic colorectal cancer. Methods A retrospective population‐based study was conducted on patients with metastatic colorectal cancer in Central Finland in 2000–2015. Clinical and histopathological data were retrieved and descriptive analysis was conducted to determine the pattern of metastatic disease, defined as synchronous, early metachronous (within 12 months of diagnosis of primary disease) and late metachronous (more than 12 months after diagnosis). Subgroups were compared for resection and overall survival (OS) rates. Results Of 1671 patients, 296 (17·7 per cent)…

MaleLung NeoplasmsPROGNOSISColorectal cancerGastroenterology0302 clinical medicineEpidemiologyEPIDEMIOLOGYStage (cooking)FinlandAged 80 and overeducation.field_of_studyIncidenceIncidence (epidemiology)Liver NeoplasmsGeneral MedicineMiddle Aged3. Good healthSurvival Ratemedicine.anatomical_structureHPB030220 oncology & carcinogenesisSURVIVALLower GIFemaleOriginal Article030211 gastroenterology & hepatologysyöpätauditMetastasectomyColorectal Neoplasmsmedicine.medical_specialtyRESECTIONesiintyvyysPopulationlcsh:Surgerycolorectal cancersuolistosyövätLIVER METASTASESetäpesäkkeet03 medical and health sciencesInternal medicinemedicineHumanseducationAgedRetrospective StudiespaksusuolisyöpäLungbusiness.industryMetastasectomyRetrospective cohort studyOriginal Articleslcsh:RD1-8113126 Surgery anesthesiology intensive care radiologymedicine.diseasebusiness
researchProduct

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial

2018

Abstract Aim of the study The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting. Patients and methods Chemotherapy-naive patients received at least 8 cycles of FOLFIRINOX. The primary end-point was the 4-month disease control (4 m DC) rate. Tumour responses were centrally reviewed and assessed by computed tomography scan for metastases (Response Evaluation Criteria in Solid Tumours criteria) and magnetic resonance imaging for rectal tumorus. With a Simon 2-stage design and a targeted (H1) 4 m DC > 75%, 65 patients were enrolled from July 2012 to Februa…

MaleCancer ResearchLung NeoplasmsColorectal cancerFOLFIRINOXGastrointestinal DiseasesSynchronous metastasesLeucovorinKaplan-Meier EstimateInduction0302 clinical medicineInduction therapyAntineoplastic Combined Chemotherapy ProtocolsRectal cancerINDUCTION TREATMENTFatigueResponse rate (survey)medicine.diagnostic_testLiver NeoplasmsRemission InductionMiddle AgedCombined Modality TherapyMagnetic Resonance ImagingProgression-Free Survival3. Good healthOxaliplatinFOLFIRINOXTreatment OutcomeOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleRadiologyFluorouracilAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaIrinotecan03 medical and health sciencesmedicineHumansParesthesiaAgedPerformance statusbusiness.industryRectal NeoplasmsMagnetic resonance imagingmedicine.diseaseHematologic DiseasesConfidence intervalLocal controlbusinessTomography X-Ray ComputedFollow-Up Studies
researchProduct